Table of contents
July 2006 Vol 5 No 7
In This Issue
p523 | doi:10.1038/nrd2101
Editorial: Keeping sight of the goal
p525 | doi:10.1038/nrd2102
News and Analysis
Industry anger over stringent trial disclosure requirements | PDF (735 KB)
p527 | doi:10.1038/nrd2103
Safety concerns raised over RNA interference | PDF (296 KB)
p528 | doi:10.1038/nrd2104
News in Brief
| PDF (232 KB)
p530 | doi:10.1038/nrd2105
Patent watch
Vaccines give written description guidance | Merck misses its mark | Ubiquitin–proteasome system modulation | PDF (109 KB)
p532 | doi:10.1038/nrd2106
An Audience With
John A. Fraser | PDF (61 KB)
p534 | doi:10.1038/nrd2107
From the analyst's couch
Biosimilars: initial excitement gives way to reality | PDF (341 KB)
p535 | doi:10.1038/nrd2093
Fresh from the Pipeline
Varenicline | PDF (148 KB)
p537 | doi:10.1038/nrd2088
Research Highlights
Antibacterial drugs: New antibiotic on the horizon? | PDF (417 KB)
p539 | doi:10.1038/nrd2098
Neurological disorders: Homing in on the target of antidepressants | PDF (109 KB)
p540 | doi:10.1038/nrd2095
Liver disease: A new treatment for liver fibrosis? | PDF (81 KB)
p540 | doi:10.1038/nrd2096
Sepsis: Unpicking the pathogenesis of sepsis | PDF (109 KB)
p541 | doi:10.1038/nrd2097
Screening: Dirty drugs' secrets uncovered | PDF (89 KB)
p542 | doi:10.1038/nrd2099
In brief
Drug delivery | Parkinson's disease | Antiinfectives | Kinase inhibitors | PDF (106 KB)
p542 | doi:10.1038/nrd2100
Perspectives
Innovation
Current status and future prospects of needle-free liquid jet injectors
Samir Mitragotri
p543 | doi:10.1038/nrd2076
Needle-free liquid jet injectors have been used for over five decades for delivery of numerous vaccines and drugs such as insulin, growth hormones and anaesthetics. Mitragotri reviews jet injectors with respect to their clinical and emerging applications, mechanistic understanding and future prospects.
Reviews
Targeting signal transduction as a strategy to treat inflammatory diseases
Luke A. J. O'Neill
p549 | doi:10.1038/nrd2070
Recent advances in our understanding of the signalling pathways activated in inflammation have revealed several potential therapeutic targets. O'Neill reviews these pathways and speculates on the likelihood of drugs being developed that will limit inflammation without a deleterious impact on host defence.
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Jeffrey L. Browning
p564 | doi:10.1038/nrd2085
The recent success of the B-cell-depleting antibody rituximab — originally developed as a lymphoma therapy — in the treatment of rheumatoid arthritis has stimulated considerable interest in the potential of drugs that can modulate B-cell function to treat autoimmune disorders. Browning discusses the role of B cells in a range of such disorders and analyses approaches to therapeutic B-cell manipulation.
Telomerase therapeutics for cancer: challenges and new directions
Jerry W. Shay & Woodring E. Wright
p577 | doi:10.1038/nrd2081
Telomerase is expressed by cancer cells where it contributes to tumour maintenance, but is absent from most normal cells. Strategies for targeting telomerase therefore provide new opportunities for targeted cancer therapy. Shay and Wright review the current status and future opportunities for telomerase therapeutics.
Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes
Steven A. Hofstadler & Kristin A. Sannes-Lowery
p585 | doi:10.1038/nrd2083
Mass spectrometry is emerging as a powerful analytical tool at various key stages in the drug discovery process. Hofstadler and Sannes-Lowery review the application of electrospray ionization mass spectrometry in the characterization of noncovalent complexes in drug discovery efforts against several classes of target.
Drug discovery in the ubiquitin–proteasome system
Grzegorz Nalepa, Mark Rolfe & J. Wade Harper
p596 | doi:10.1038/nrd2056
The ubiquitin–proteasome pathway contains a large number of components that are possible drug targets for cancer and other diseases. Nalepa et al. review evidence linking components of this pathway to human disease and discuss potential strategies for therapeutic intervention.
Erratum: Ranolazine
Jonathan Abrams, Carole A. Jones & Peter Kirkpatrick
| doi:10.1038/nrd2108
